Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206
Maria Lteif, Myriam Nabhan, Cécile Tardif, Claire Smadja, Jennifer Mata-Orozco, Stéphane Hua, Bernard Maillère, Marc Pallardy, Isabelle Turbica · 2026
Read Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206 by Maria Lteif, Myriam Nabhan, Cécile Tardif, Claire Smadja, Jennifer Mata-Orozco, Stéphane Hua, Bernard Maillère, Marc Pallardy, Isabelle Turbica (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582642.txt.
Description
Maria Lteif and co-authors probe why clumped drug antibodies stir up the immune system in this 2026 study. The test drug is infliximab, an antibody used against inflammatory disease. When antibody molecules stick together into tiny clusters, patients are more likely to react against the drug itself.
The team made nano-sized clusters by shining ultraviolet light on the drug. In lab cultures, the clusters woke up far more drug-specific T cells than the loose drug did. Different T cells answered each form. Dendritic cells, the scouts that show material to T cells, swallowed clusters faster through a sugar-sensing route. The findings explain part of the risk that particle limits in drug rules try to control.
Catalog record
| CREATOR | Maria Lteif, Myriam Nabhan, Cécile Tardif, Claire Smadja, Jennifer Mata-Orozco, Stéphane Hua, Bernard Maillère, Marc Pallardy, Isabelle Turbica |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |